Pulmonary Hypertension in General Cardiology Practice

Abstract

The finding of pulmonary hypertension (PH) by echocardiography is common and of concern. However, echocardiography is just a suggestive and non-diagnostic assessment of PH. When direct involvement of pulmonary circulation is suspected, invasive hemodynamic monitoring is recommended to establish the diagnosis. This assessent provides, in addition to the diagnostic confirmation, the correct identification of the vascular territory predominantly involved (arterial pulmonary or postcapillary). Treatment with specific medication for PH (phosphodiesterase type 5 inhibitors, endothelin receptor antagonists and prostacyclin analogues) has been proven effective in patients with pulmonary arterial hypertension, but its use in patients with PH due to left heart disease can even be damaging. In this review, we discuss the diagnosis criteria, how etiological investigation should be carried out, the clinical classification and, finally, the therapeutic recommendations for PH.

Oxidative Stress Associated with SARS-Cov-2 (COVID-19) Increases the Severity of the Lung Disease - A Systematic Review

“…or supplement deficient antioxidants, in particular GSH and non-enzymatic antioxidants, including vitamins and trace elements; or trap the ROS directly [61]. Each of these categories of therapeutic approaches, most of which have ultimately had little or no success in treating pulmonary or pulmonary vascular disease [62]. But in parallel with the recommendation of one of these approaches there are problems concerning the chosen dose, with the half-life of the antioxidants supplemented; targeting of the appropriate tissue, organ or cells; type of patient and disease and according to the type of physiological disturbance of the oxidants [63].…”

Atualização no Tratamento da Hipertensão Arterial Pulmonar

“…HP seja doença cardíaca esquerda e aumento da pressão hidrostática do sistema, a partir do átrio esquerdo. 14 O grupo III inclui pacientes com HP por doença pulmonar crônica, nos quais a gênese da enfermidade advém da perda do leito vascular pulmonar e da vasoconstrição hipóxica. 15 O grupo IV inclui pacientes com HP por embolia pulmonar crônica (HPTEC), e possui um manejo clínico distinto, além do escopo deste texto.…”

Inhaled iloprost as third add‐on therapy in idiopathic pulmonary arterial hypertension

“…Pulmonary arterial hypertension (PAH) is a progressive and life-threatening disease characterized by vascular proliferation and endothelial remodeling that leads to an increase in pulmonary vascular resistance (PVR) and ultimately right heart failure and death. 1 Current pharmacological PAH treatment includes drugs from three distinct biochemical pathways: prostacyclin, endothelin, and nitric oxide. 2 These drugs can be used in monotherapy or combination, determined by the PAH etiology and the severity of the disease.…”